A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy

NCT04230044 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2020-01-18

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of Fycompa® (perampanel) for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy aged 12 years and older.

Conditions

Interventions

DRUG

Perampanel

Perampanel tablets.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-11
Primary Completion
2017-07-03
Completion
2017-07-03

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04230044 on ClinicalTrials.gov